Patents Examined by Kamal Saeed
  • Androgen receptor modulating compounds
    Patent number: 11046713
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: June 29, 2021
    Assignee: ORION CORPORATION
    Inventors: Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, Iisa Höglund, Arja Karjalainen, Pia Koivikko, Patrik Holm, Sirpa Rasku, Anniina Vesalainen
  • Activators of the unfolded protein response
    Patent number: 11046647
    Abstract: A set of small molecules ER? biomodulators that kill therapy-resistant ER? positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: June 29, 2021
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: David J. Shapiro, Paul J. Hergenrother, Matthew W. Boudreau
  • Oxazolidinone for treatment of infections with
    Patent number: 11040025
    Abstract: The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N-(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: June 22, 2021
    Assignees: The Johns Hopkins University, University of St. Thomas
    Inventors: Gyanu Lamichhane, J. Thomas Ippoliti
  • Liver X receptor (LXR) modulators
    Patent number: 11034657
    Abstract: Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of LXR-associated diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: June 15, 2021
    Assignee: ELLORA THERAPEUTICS, INC.
    Inventor: Raju Mohan
  • 1,3-dipolar compound bearing an imidazole functional group
    Patent number: 11034780
    Abstract: In a 1,3-dipolar compound of formula Q-A-B, Q comprises a dipole containing at least and preferably one nitrogen atom, A, which is preferably divalent, is an atom or a group of atoms connecting Q to B, and B comprises an imidazole ring. An unsaturated polymer modified by grafting the 1,3-dipolar compound is also disclosed.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 15, 2021
    Assignee: COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
    Inventors: Oleg Ugolnikov, Sergey Ivanov, Claire Rannoux, Anne-Frédérique Salit, Sophie Gander, Anne-Lise Thuilliez
  • Pyrazole amide compound and use thereof
    Patent number: 11033029
    Abstract: Disclosed is a pyrazole amide compound as represented by general formula I, wherein, R1 is selected from hydrogen, C1-C4 alkyl, C2-C6 alkenyl and C2-C6 alkyl; and R2 and R3 can be the same or different, and are respectively and independently selected from the C1-C6 alkyl. The general formula I compound has an excellent bactericidal activity, and can be used to prevent and control fungal diseases.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: June 15, 2021
    Assignee: SHENYANG SINOCHEM AGROCHEMICALS R & D CO., LTD.
    Inventors: Liang Lv, Yugang Li, Zhonggang Shan, Shasha Wu, Bin Wang, Jiyong Liu, Peng Liu, Jizhong Zhou, Huibin Yang, Bin Li
  • Substituted N?-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors
    Patent number: 11034661
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: June 15, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Liangqin Guo, Yongxin Han, Kun Liu, Shuwen He, Joseph Kozlowski, Ravi Nargund, Wensheng Yu, Hongjun Zhang, Qinglin Pu, Derun Li, Abdelghani Achab, Guoqing Li
  • Compounds useful as modulators of TRPM8
    Patent number: 11028052
    Abstract: The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formulae (Ia), (Ib) and (Ic), and the subgenus and species thereof; personal products containing those compounds; and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: June 8, 2021
    Assignee: Firmenich Incorporated
    Inventors: Lyudmyla Chumakova, Andrew Patron, Chad Priest, Donald Karanewsky, Rachel Kimmich, Brant Clayton Boren, Jeffrey Robert Hammaker, Volodymyr Chumakov, Wen Zhao, Alain Noncovich, Jane Ung
  • Compositions and methods for modulating farnesoid X receptors
    Patent number: 11021446
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: June 1, 2021
    Assignee: Novartis AG
    Inventors: Donatella Chianelli, Runyan Li, Valentina Molteni, John Nelson, Jason Thomas Roland, Paul Vincent Rucker, David Charles Tully, Xiaoyang Wang, Liladhar Murlidhar Waykole, Yubo Zhang, Bo Zhou
  • Crystalline form of lorlatinib free base
    Patent number: 11020376
    Abstract: This invention relates to acrystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7). This invention also relates to pharmaceutical compositions comprising Form 7, and to methods of using Form 7 and such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: June 1, 2021
    Assignee: Pfizer Inc.
    Inventors: Klimentina Dimitrova Pencheva, Melissa Jane Birch, Stephen Mark McAllister, Martin Gregory Rowland, Ian Leonard Smales
  • Methyllactam ring compound and pharmaceutical use thereof
    Patent number: 11014910
    Abstract: An object of the present invention is to provide a methyllactam ring compound that has an SGLT1 inhibitory activity and is useful for a drug, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it, and pharmaceutical use thereof. A compound of Formula [I]: or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it, and pharmaceutical use thereof is provided.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: May 25, 2021
    Assignee: JAPAN TOBACCO INC.
    Inventors: Tomoya Miura, Yoshinori Tamatani
  • Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients
    Patent number: 11000038
    Abstract: A pyridone compound represented by Formula (1): wherein R1, R2, X, Y and Z are defined. The pyridone compound can control plant diseases.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: May 11, 2021
    Assignee: MITSUI CHEMICALS AGRO, INC.
    Inventors: Hideki Umetani, Kazuki Kitajima, Takeshi Fukumoto, Masanori Yanagi, Akihiro Nishida, Ryohei Naito, Koya Saito, Tomomi Shirakawa, Hikaru Koishihara, Akane Sakurada, Satoshi Yutani, Toshiaki Ohara
  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 11001571
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: May 11, 2021
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • Citric acid derivative
    Patent number: 11001573
    Abstract: Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein R1 represents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and R2 represents a hydrogen atom, or R1 and R2 optionally form a cyclic structure together to represent a C2 to C3 alkylene chain).
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: May 11, 2021
    Assignees: ADABIO CO., LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.
    Inventors: Katsuya Hiraishi, Fumie Jimma, Hiroyuki Soma, Taro Adachi, Masakazu Adachi, Ippei Yamaoka, Tomohiro Kagawa
  • Substituted n?-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Patent number: 10988487
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: April 27, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kun Liu, Abdelghani Achab, Purakkattle Biju, Timothy A. Cernak, Yongqi Deng, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Joseph Kozlowski, Derun Li, Guoqing Li, Qinglin Pu, Zhi-Cai Shi, Wensheng Yu, Hongjun Zhang
  • Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
    Patent number: 10988462
    Abstract: Pyrazole compounds substituted with heteroaryl or pharmaceutically acceptable salts thereof that have an SGLT1 inhibitory activity and are useful for a drug, pharmaceutical compositions comprising the same, and pharmaceutical use thereof are disclosed. Specifically, a compound of Formula [X]: wherein R1 is hydrogen or halogen, R2 is C1-6 alkyl or halo-C1-6 alkyl, Ring Het is substituted pyridyl or optionally substituted pyrazinyl, pyrimidinyl, or pyridazinyl, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it, and pharmaceutical use thereof is provided.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: April 27, 2021
    Assignee: Japan Tobacco Inc.
    Inventors: Tomoya Miura, Shintaro Hirashima, Tomoyuki Manabe, Tetsuya Iida, Kentaro Sakurai
  • FXR (NR1H4) modulating compounds
    Patent number: 10981881
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: April 20, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Jianjun Xu
  • Production method for pyrazole-amide compound
    Patent number: 10981877
    Abstract: A production method of a compound represented by the formula [I]: or a pharmaceutically acceptable salt thereof, or a hydrate thereof.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: April 20, 2021
    Assignee: JAPAN TOBACCO INC.
    Inventors: Takahisa Motomura, Masafumi Inoue, Hirotsugu Ito, Takuya Matsuo, Koichi Suzawa, Hiroshi Yamamoto, Tsubasa Takeichi, Yasuyuki Kajimoto, Takashi Inaba, Takao Ito, Takahiro Yamasaki, Yukishige Ikemoto
  • 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles and methods of use
    Patent number: 10980781
    Abstract: The present invention generally relates to 6-amino-2,4-dihydropyrano [2,3-c] pyrazoles as a ubiquitin specific protease 7(USP7) inhibitor useful for the treatment of diseases mediated by malfunction of USP7, such as inflammation, cancer, and immunological disorders. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases mediated by malfunction of USP7, in mammals using compounds disclosed herein.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: April 20, 2021
    Assignee: Purdue Research Foundation
    Inventors: Antonella Pepe, Andrew Mesecar
  • Compound for inhibiting IDO, a manufacturing method and a use thereof
    Patent number: 10981882
    Abstract: A compound for inhibiting IDO represented by the following general formula I, wherein a bond represented by a wavy line “” indicates the structure which represents independently a cis-isomer, a trans-isomer, or a mixture of cis- and trans-isomers; R1 and R2 are each independently selected from the group consisting of H, halogen, alkyl, alkoxyl, and haloalkyl; R3 is selected from the group consisting of cyclopentyl, cyclohexyl, piperazinyl, and piperidyl; and the substitution positions of R3 are optionally substituted at 1,2 position, 1,3 position or 1,4 position; m and n are an integer number independently selected from 0 to 5. The compound has a strong inhibiting effect on IDO and can be used to manufacture an IDO inhibitor for the prevention and/or treatment of an IDO-mediated disease with the pathologic features of the tryptophan metabolic pathway.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: April 20, 2021
    Assignee: Shanghai JOYU Pharmatech Ltd.
    Inventors: Yan Zhong, Xirong Cao, Yonglin Wang